In lean MASLD with visceral adiposity (and/or high-risk metabolic/genetic features) in an already physically active patient, when do you recommend additional weight loss versus focusing on diet quality and central adiposity reduction, and how do you monitor to avoid clinically meaningful loss of lean mass?
1 Answer
Mednet MemberInvited Expert
Hepatology · Penn State College of Medicine
Answered on
In lean MASLD, current practice guidance would prioritize reduction of visceral adiposity and improvement in metabolic health rather than pursuing arbitrary WL targets, particularly in patients who are already physically active and have a normal BMI. In this setting, I focus on diet quality (Mediter...
Join for free or sign in to see the full answer